ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

EVOTAZ
Viral infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

EVOTAZ Rx

Generic Name and Formulations:
Atazanavir 300mg, cobicistat 150mg; tabs.

Company:
Bristol-Myers Squibb

Therapeutic Use:

Indications for EVOTAZ:

HIV-1 infection in combination with other antiretroviral agents.

Limitations Of use:

Use in treatment-experienced patients should be guided by number of baseline primary protease inhibitor resistance substitutions.

Adult:

Take with food. 1 tab daily.

Children:

<18yrs: not established.

Contraindications:

Concomitant alfuzosin, ranolazine, dronedarone, carbamazepine, phenobarbital, phenytoin, colchicine (in renal/hepatic impaired), rifampin, irinotecan, lurasidone, pimozide, triazolam, oral midazolam, ergots, cisapride, elbasvir/grazoprevir, St. John's wort, lovastatin, simvastatin, nevirapine, sildenafil (for PAH), indinavir.

Warnings/Precautions:

Assess CrCl prior to initiation. Concomitant tenofovir DF: assess baseline CrCl, urine glucose, and urine protein; if CrCl <70mL/min: not recommended; monitor serum phosphorous if risk of renal impairment. ESRD with hemodialysis in treatment-experienced or hepatic impairment: not recommended. Cardiac conduction abnormalities; consider ECG monitoring if preexisting marked 1st -degree AV block or 2nd/3rd -degree AV block. Consider interruption or discontinuation if nephrolithiasis or cholelithiasis occurs. Hepatitis B and/or C or marked elevations in transaminases: monitor LFTs before and during therapy. Consider alternative if jaundice or scleral icterus occurs. Diabetes. Hemophilia. Elderly. Pregnancy. Nursing mothers: not recommended.

Interactions:

See Contra­in­di­ca­tions. Separate dosing with concomitant H2 receptor antagonists, PPIs (not recommended in treatment-experienced), antacids, enteric-coated didanosine. Concomitant tenofovir DF with concomitant or recent nephrotoxic agents, other antiretrovirals that require CYP3A inhibition (eg, HIV protease inhibitors, elvitegravir), ritonavir or ritonavir-containing products, CYP2C8 substrates with narrow therapeutic indices (eg, paclitaxel, repaglinide), efavirenz, etravirine, boceprevir, simeprevir, apixaban, rivaroxaban, dabigatran etexilate, avanafil, inhaled/nasal steroids, salmeterol, voriconazole: not recommended. May need to adjust dose of insulin, antidiabetics, dasatinib, nilotinib, sildenafil, tadalafil, vardenafil, perphenazine, risperidone, thioridazine, buprenorphine, naloxone, methadone, tramadol, bosentan, rifabutin, and sedatives/hypnotics. Concomitant maraviroc: give maraviroc 150mg twice daily. Potentiates quetiapine: consider alternative antiretrovirals; if coadministration necessary, reduce quetiapine to ⅙ of current dose and monitor. Monitor concomitant antiarrhythmics, digoxin, vincristine, vinblastine, warfarin, clonazepam, lamotrigine, SSRIs, TCAs, trazodone, fentanyl, immunosuppressants, other statins, β-blockers, CCBs. Concomitant clarithromycin, erythromycin, telithromycin, CYP3A-inducing anticonvulsants (eg, eslicarbazepine, oxcarbazepine), systemic corticosteroids (eg, dexamethasone): consider alternatives. See full labeling.

Pharmacological Class:

HIV-1 protease inhibitor + CYP3A inhibitor.

Adverse Reactions:

Jaundice, rash (may be severe; discontinue if occurs), ocular icterus; hyperbilirubinemia, fat redistribution, immune reconstitution syndrome.

Generic Availability:

NO

How Supplied:

Tabs—30

Sign Up for Free e-newsletters